Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The pre-proinsulin peptide–HLA-A*02:01 complex is a molecular complex formed by the binding of an epitope from human preproinsulin (commonly the 3–11 region, such as LWMRLLPLL) to the HLA-A*02:01 major histocompatibility complex class I molecule. This complex is presented on the surface of cells (notably pancreatic beta cells) and can be specifically recognized by CD8+ T cell receptors. In type 1 diabetes, autoreactive cytotoxic T cells target these complexes, leading to immune-mediated destruction of insulin-producing beta cells. The complex represents a key autoimmune target and is a central mechanistic component in the pathogenesis of type 1 diabetes[2][4]. Molecular mimicry with microbial peptides may also break immune tolerance, contributing to disease initiation[4]. Key considerations: - This entry describes a peptide–MHC (major histocompatibility complex) complex, not a traditional 'single protein' drug target like a receptor or enzyme. It is, however, the functional epitope recognized by pathogenic T cells in type 1 diabetes[2][4]. - Therapeutic strategies (including engineered T cell receptors, immune tolerance induction, or peptide-based immunomodulation) may target this complex, but there are no approved drugs directly targeting it[2][4]. - As a peptide–MHC complex, it is highly relevant in immunology and autoimmunity research, but not typically considered a canonical pharmacological molecular target (hence is_incorrect: true). If you require a strictly canonical protein target (like "Insulin" or "HLA-A*02:01"), the above entry is too complex/specific as given. If you require antigen/MHC complexes driving T cell responses, this entry is relevant but does not fit standardized molecular target databases.
T cell recognition (CD8+ cytotoxic T lymphocyte activation via recognition of the complex by T cell receptor)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pre-proinsulin peptide–HLA-A*02:01 complex.